Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations | BMC Cancer User montaukwhaler, in the non small cell lung cancer subreddit, 05 Sep 2020